VB
Valiveti Brahmaji
About Valiveti Brahmaji
Data last updated:
Valiveti Brahmaji is a Director at Difgen Pharmaceuticals Private Limited (since 2025), Director at Riconpharma India Private Limited (since 2014) and Additional Director at Prathyak Laboratories Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Research & Development, Pharma and Life Sciences. The 4 current companies with reported revenue have a combined latest revenue of ₹104 Cr; the largest is Difgen Pharmaceuticals Private Limited at ₹76.63 Cr (FY 2025). Earlier, Valiveti Brahmaji was a Director at Odisha Biotech Park Private Limited (2009–2015) and Director at Arch Life Sciences Limited (2003–2008) and 3 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 21 Jan 2025 | 2022 | ₹76.63 Cr (FY 2025) | Active | |
| Director | 01 Oct 2014 | 2009 | ₹27.30 Cr (FY 2024) | Active | |
| Additional Director | 28 Jul 2025 | 2022 | ₹7.5 Lakh (FY 2025) | Active | |
| Director | 21 Mar 2022 | 2022 | ₹3.3 Lakh (FY 2025) | Active | |
| Director | 28 Jul 2025 | 2022 | Active | ||
| Director | 14 Jun 2008 | 2007 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 23 Jun 2009 | 2009 | ₹17.2 Lakh (FY 2025) | Active | |
| Director | 15 Dec 2003 | 2003 | ₹10,510 (FY 2024) | Active | |
| Director | 22 Jun 2006 | 2006 | ₹15.3 Lakh (FY 2024) | Active | |
| Director | 27 Apr 2009 | 2008 | ₹89.48 Cr (FY 2025) | Active | |
| Director | 04 Jan 2008 | 2007 | ₹58.4 Lakh (FY 2022) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Valiveti Brahmaji
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Valiveti Brahmaji
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valiveti Brahmaji
Valiveti Brahmaji currently holds 6 directorships: Difgen Pharmaceuticals Private Limited (Director, since 21 Jan 2025, revenue ₹76.63 Cr (FY 2025)); Riconpharma India Private Limited (Director, since 01 Oct 2014, revenue ₹27.30 Cr (FY 2024)); Prathyak Laboratories Private Limited (Additional Director, since 28 Jul 2025, revenue ₹7.5 Lakh (FY 2025)); Fermac Bio Private Limited (Director, since 21 Mar 2022, revenue ₹3.3 Lakh (FY 2025)); Vivint Pharma Private Limited (Director, since 28 Jul 2025); and 1 more.
Valiveti Brahmaji was first appointed on 15 Dec 2003 as Director at Arch Life Sciences Limited. The most recent appointment on record is 28 Jul 2025 at Vivint Pharma Private Limited.
The 4 current companies of Valiveti Brahmaji that report revenue have a combined latest revenue of ₹104 Cr: Difgen Pharmaceuticals Private Limited ₹76.63 Cr (FY 2025); Riconpharma India Private Limited ₹27.30 Cr (FY 2024); Prathyak Laboratories Private Limited ₹7.5 Lakh (FY 2025); Fermac Bio Private Limited ₹3.3 Lakh (FY 2025).
Valiveti Brahmaji held 5 earlier board appointments: Odisha Biotech Park Private Limited (Director, 23 Jun 2009 to 28 Feb 2015); Arch Life Sciences Limited (Director, 15 Dec 2003 to 13 Feb 2008); Vekap Ventures Private Limited (Director, 22 Jun 2006 to 26 Dec 2020); Verdant Life Sciences Private Limited (Director, 27 Apr 2009 to 07 Sep 2019); Sierra Agro Private Limited (Director, 04 Jan 2008 to 28 Nov 2018).
The current boards of Valiveti Brahmaji's companies include Amol Ashok Walke (Difgen Pharmaceuticals Private Limited), Krishna Chandrasekaran (Difgen Pharmaceuticals Private Limited), Narasimhan Sridhar Nagaarjun (Difgen Pharmaceuticals Private Limited), Punit Chunilal Thakrar (Difgen Pharmaceuticals Private Limited), Ramandeep Singh Jaj (Difgen Pharmaceuticals Private Limited), Santhanakrishnan Srinivasan (Difgen Pharmaceuticals Private Limited), among others.